Skye Bioscience (SKYE) Current Taxes (2012 - 2016)

Skye Bioscience (SKYE) posted quarterly Current Taxes of $800.0 for Q2 2016, up 100.0% quarter-over-quarter from $400.0 in Q1 2016.

Skye Bioscience (SKYE) Current Taxes (2012 - 2016) Analysis & Trends

Skye Bioscience (SKYE) has reported Current Taxes for 5 consecutive years, with $800.0 the latest figure, recorded in Q2 2016.

In Q2 2016, Current Taxes changed N/A year-over-year to $800.0; the TTM figure through Jun 2016 stood at $800.0 (changed N/A YoY), while the FY2014 annual figure was $800.0, changed N/A from the prior year.
Current Taxes climbed to $800.0 in Q2 2016 per SKYE's latest filing, from $400.0 in the prior quarter.
Across five years, Current Taxes topped out at $1384.0 in Q2 2013 and bottomed at $246.0 in Q4 2012.
Historically, Current Taxes has averaged $659.71 across 5 years, with a median of $588.0 in 2013.
On a YoY basis, Current Taxes climbed as much as 0.0% in 2016 and fell as far as 0.0% in 2016.
Skye Bioscience's Current Taxes stood at $246.0 in 2012, then jumped by 139.02% to $588.0 in 2013, then soared by 36.05% to $800.0 in 2014, then slumped by 50.0% to $400.0 in 2015, then surged by 100.0% to $800.0 in 2016.
Business Quant data shows SKYE's Current Taxes at $800.0 in Q2 2016, $400.0 in Q1 2016, and $400.0 in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Taxes (Qtr)
1	Vertex Pharmaceuticals	139.70 Bn	131.85 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.74 Bn	78.75 Bn	3.93 Bn	-
3	Argenx Se	65.36 Bn	60.18 Bn	1.37 Bn	49.00 Mn
4	Moderna	59.15 Bn	54.01 Bn	52.00 Mn	-
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	76.32 Mn
6	Alnylam Pharmaceuticals	31.88 Bn	28.57 Bn	992.69 Mn	-
7	BioNTech SE	28.14 Bn	9.75 Bn	668.28 Mn	76.36 Mn
8	Insmed	27.59 Bn	26.43 Bn	358.27 Mn	-
9	Royalty Pharma	27.31 Bn	26.48 Bn	-	-
10	Skye Bioscience	10.56 Mn	10.56 Mn	-	-

Download Data